Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezdiffra, a therapy for non-alcoholic steatohepatitis (NASH). Not only was Rezdiffra Madrigal's first product on the market.
Open FlipThis has been a much different investing year than 2023. While it started off nearly the same, with practically any stock tied to artificial intelligence (AI) rising, some of the companies have been under greater scrutiny. That's exactly what happened to Snowflake (NYSE: SNOW), which is now down 30% from its 2024 highs, last reached at the end of February.
Open FlipHow To Earn $500 A Month From Williams-Sonoma Stock Ahead Of Q1 Earnings. Williams-Sonoma, Inc. (NYSE:WSM) is expected to release earnings results for its first quarter, before the opening bell on Wednesday. Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.68 per share, up from $2.64 per share in the year-ago period.
Open Flip